100 related articles for article (PubMed ID: 16467866)
1. Hyperforin inhibits MMP-9 secretion by B-CLL cells and microtubule formation by endothelial cells.
Quiney C; Billard C; Mirshahi P; Fourneron JD; Kolb JP
Leukemia; 2006 Apr; 20(4):583-9. PubMed ID: 16467866
[TBL] [Abstract][Full Text] [Related]
2. Antidepressant hyperforin up-regulates VEGF in CNS tumour cells.
Tassone E; Maran C; Masola V; Bradaschia A; Garbisa S; Onisto M
Pharmacol Res; 2011 Jan; 63(1):37-43. PubMed ID: 20883786
[TBL] [Abstract][Full Text] [Related]
3. Pro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemia.
Quiney C; Billard C; Faussat AM; Salanoubat C; Ensaf A; Naït-Si Y; Fourneron JD; Kolb JP
Leukemia; 2006 Mar; 20(3):491-7. PubMed ID: 16424868
[TBL] [Abstract][Full Text] [Related]
4. Hyperforin, a bio-active compound of St. John's Wort, is a new inhibitor of angiogenesis targeting several key steps of the process.
Martínez-Poveda B; Quesada AR; Medina MA
Int J Cancer; 2005 Dec; 117(5):775-80. PubMed ID: 15981212
[TBL] [Abstract][Full Text] [Related]
5. Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumor-induced lymphangiogenesis in vivo.
Rothley M; Schmid A; Thiele W; Schacht V; Plaumann D; Gartner M; Yektaoglu A; Bruyère F; Noël A; Giannis A; Sleeman JP
Int J Cancer; 2009 Jul; 125(1):34-42. PubMed ID: 19326439
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic insights into the antileukemic activity of hyperforin.
Billard C; Merhi F; Bauvois B
Curr Cancer Drug Targets; 2013 Jan; 13(1):1-10. PubMed ID: 22924417
[TBL] [Abstract][Full Text] [Related]
7. Hyperforin inhibits P-gp and BCRP activities in chronic lymphocytic leukaemia cells and myeloid cells.
Quiney C; Billard C; Faussat AM; Salanoubat C; Kolb JP
Leuk Lymphoma; 2007 Aug; 48(8):1587-99. PubMed ID: 17701591
[TBL] [Abstract][Full Text] [Related]
8. Hyperforin, a new lead compound against the progression of cancer and leukemia?
Quiney C; Billard C; Salanoubat C; Fourneron JD; Kolb JP
Leukemia; 2006 Sep; 20(9):1519-25. PubMed ID: 16791262
[TBL] [Abstract][Full Text] [Related]
9. Hyperforin acts as an angiogenesis inhibitor.
Schempp CM; Kiss J; Kirkin V; Averbeck M; Simon-Haarhaus B; Kremer B; Termeer CC; Sleeman J; Simon JC
Planta Med; 2005 Nov; 71(11):999-1004. PubMed ID: 16320199
[TBL] [Abstract][Full Text] [Related]
10. Hyperforin induces apoptosis of chronic lymphocytic leukemia cells through upregulation of the BH3-only protein Noxa.
Zaher M; Tang R; Bombarda I; Merhi F; Bauvois B; Billard C
Int J Oncol; 2012 Jan; 40(1):269-76. PubMed ID: 21947285
[TBL] [Abstract][Full Text] [Related]
11. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line.
Tian R; Koyabu N; Morimoto S; Shoyama Y; Ohtani H; Sawada Y
Drug Metab Dispos; 2005 Apr; 33(4):547-54. PubMed ID: 15640377
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis.
Schempp CM; Kirkin V; Simon-Haarhaus B; Kersten A; Kiss J; Termeer CC; Gilb B; Kaufmann T; Borner C; Sleeman JP; Simon JC
Oncogene; 2002 Feb; 21(8):1242-50. PubMed ID: 11850844
[TBL] [Abstract][Full Text] [Related]
13. Modulation of P-glycoprotein function by St John's wort extract and its major constituents.
Weber CC; Kressmann S; Fricker G; Müller WE
Pharmacopsychiatry; 2004 Nov; 37(6):292-8. PubMed ID: 15551196
[TBL] [Abstract][Full Text] [Related]
14. Tetrahydrohyperforin and octahydrohyperforin are two new potent inhibitors of angiogenesis.
Martínez-Poveda B; Verotta L; Bombardelli E; Quesada AR; Medina MA
PLoS One; 2010 Mar; 5(3):e9558. PubMed ID: 20224821
[TBL] [Abstract][Full Text] [Related]
15. Hyperforin blocks neutrophil activation of matrix metalloproteinase-9, motility and recruitment, and restrains inflammation-triggered angiogenesis and lung fibrosis.
Dell'Aica I; Niero R; Piazza F; Cabrelle A; Sartor L; Colalto C; Brunetta E; Lorusso G; Benelli R; Albini A; Calabrese F; Agostini C; Garbisa S
J Pharmacol Exp Ther; 2007 May; 321(2):492-500. PubMed ID: 17289834
[TBL] [Abstract][Full Text] [Related]
16. Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures.
Komoroski BJ; Parise RA; Egorin MJ; Strom SC; Venkataramanan R
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6972-9. PubMed ID: 16203790
[TBL] [Abstract][Full Text] [Related]
17. Hyperforin: more than an antidepressant bioactive compound?
Medina MA; Martínez-Poveda B; Amores-Sánchez MI; Quesada AR
Life Sci; 2006 Jun; 79(2):105-11. PubMed ID: 16438991
[TBL] [Abstract][Full Text] [Related]
18. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures.
Komoroski BJ; Zhang S; Cai H; Hutzler JM; Frye R; Tracy TS; Strom SC; Lehmann T; Ang CY; Cui YY; Venkataramanan R
Drug Metab Dispos; 2004 May; 32(5):512-8. PubMed ID: 15100173
[TBL] [Abstract][Full Text] [Related]
19. Hyperforin inhibits cancer invasion and metastasis.
Donà M; Dell'Aica I; Pezzato E; Sartor L; Calabrese F; Della Barbera M; Donella-Deana A; Appendino G; Borsarini A; Caniato R; Garbisa S
Cancer Res; 2004 Sep; 64(17):6225-32. PubMed ID: 15342408
[TBL] [Abstract][Full Text] [Related]
20. The main components of St John's Wort inhibit low-density lipoprotein atherogenic modification: a beneficial "side effect" of an OTC antidepressant drug?
Laggner H; Schreier S; Hermann M; Exner M; Mühl A; Gmeiner BM; Kapiotis S
Free Radic Res; 2007 Feb; 41(2):234-41. PubMed ID: 17364950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
